Green Square Capital Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,231 shares of the biopharmaceutical company’s stock after buying an additional 2,415 shares during the period. Green Square Capital Advisors LLC’s holdings in Pfizer were worth $1,927,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of PFE. Moneta Group Investment Advisors LLC lifted its position in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the last quarter. Norges Bank bought a new position in shares of Pfizer during the fourth quarter worth about $3,150,472,000. Morgan Stanley lifted its position in shares of Pfizer by 10.3% during the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after purchasing an additional 7,419,929 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after purchasing an additional 6,972,650 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in Pfizer in the first quarter worth about $311,238,000. Institutional investors own 67.80% of the company’s stock.
Insiders Place Their Bets
In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The stock was purchased at an average price of $38.58 per share, with a total value of $38,580.00. Following the purchase, the director now owns 6,000 shares of the company’s stock, valued at approximately $231,480. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.05% of the stock is currently owned by company insiders.
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.23. The firm had revenue of $18.28 billion for the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm’s quarterly revenue was down 28.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.62 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 3.35 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be given a $0.41 dividend. The ex-dividend date is Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.28%. Pfizer’s dividend payout ratio (DPR) is 32.28%.
Analysts Set New Price Targets
A number of brokerages have issued reports on PFE. Jefferies Financial Group began coverage on shares of Pfizer in a report on Monday, March 6th. They issued a “hold” rating and a $43.00 target price on the stock. JPMorgan Chase & Co. set a $45.00 target price on shares of Pfizer in a report on Monday, February 27th. Bank of America cut their target price on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a report on Friday, April 21st. Daiwa Capital Markets cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 target price on the stock. in a report on Thursday, May 11th. Finally, UBS Group dropped their price target on shares of Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $47.33.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Get a free research report on Pfizer from StockNews.com
- MarketBeat Week in Review – 6/19 – 6/23
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Five stocks we like better than Pfizer
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
